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Abstract
Multiple myeloma represents a subset of plasma cell dyscrasias characterized by the proliferation of plasma cells typically
in the bone marrow, representing approximately 1% of all cancers and 15% of hematologic malignancies. Often multiple
myeloma is limited to the skeletal system; however, a small percentage (<5%) of patients will develop extraosseous manifestations. We review the current WHO classification of plasma cell dyscrasias and use multimodality imaging including
US, CT, MRI, and PET-CT to illustrate the spectrum of extraosseous multiple myeloma in the abdomen and pelvis. Because
extraosseous multiple myeloma is associated with a poorer prognosis and decreased survival, it is important for the radiologist to become familiar with a variety of extraosseous manifestations in the abdomen and pelvis, especially in a patient with
a known diagnosis of multiple myeloma and the development of an abdominal or pelvic mass.
Keywords Multiple myeloma · Extraosseous · Plasma cell dyscrasia · Plasmacytoma

Introduction
Multiple myeloma is a monoclonal gammopathy characterized by the proliferation of plasma cells typically in the bone
marrow. It is a common malignancy in patients over the age
of 40. Median age of patients at the time of diagnosis is
approximately 65 years. It accounts for 1% of all malignancies and approximately 10% of all hematological disease.
More than 20,000 new cases are diagnosed annually in the
United States [1].
Patients most commonly present with bone pain, anemia,
renal failure, hypercalcemia, and recurrent infections. Extraosseous manifestations of multiple myeloma point to the
presence of myeloma outside the skeletal system. Classically this has been considered rare and thought to be found
in <5% of patients. However, with longer patient survival
and more sensitive imaging modalities, the incidence of
extraosseous multiple myeloma may be increasing. Still,
radiographic descriptions of extraosseous manifestations of
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multiple myeloma are limited. We review the spectrum of
extraosseous myeloma in the abdomen and pelvis utilizing
multimodality imaging.

Discussion
Pathologic classification
Plasma cell neoplasms are characterized by clonal proliferation of plasma cells in the bone marrow. The current World Health Organization (WHO) classification
places plasma cell neoplasms under the broad category of
mature B-cell neoplasms. Subcategories of mature B-cell
neoplasms include monoclonal gammopathy of unknown
significance (MGUS), Waldenstrom macroglobulinemia (WM), solitary plasmacytoma (SP), multiple myeloma (MM), extraosseous multiple myeloma (EOMM),
and monoclonal immunoglobulin deposition diseases
[2]. Diagnosis and classification predominantly rely on
patients’ symptoms and laboratory values. Commonly utilized laboratory values include total serum protein, serum
albumin, serum and urine protein electrophoresis, quantitative immunoglobulins, immunofixation in serum and
urine, B2-microglobulin, and detection of immunoglobulin
free light chains [3]. In addition, patients undergo bone
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marrow aspirate and biopsy to determine the percentage
of plasma cells and for prognostic studies [3].
MGUS is the most common type of plasma cell dyscrasia and is seen in more than 3% of the general population
aged 50 years or older [4]. The clinical significance of
MGUS is that it is considered premalignant and a precursor to MM with an overall 1% per year risk of progression
to MM. Imaging in patients with MGUS is not routinely
used, although it may be considered for those patients with
higher risk or if there is clinical concern [5].
WM is a distinct subtype of plasma cell dyscrasia characterized by lymphoplasmacytic lymphoma in the bone
marrow with an associated IgM monoclonal gammopathy
[3]. WM is rare with an incidence of approximately 3 per
million people per year [6]. Clinical and radiologic features are similar to lymphoma with bulky lymphadenopathy and hepatosplenomegaly [3].
Asymptomatic smoldering myeloma (SMM) refers
to a stage of myeloma, which is often a precursor to the
development of multiple myeloma. There is an increased
circulating M protein greater than 3g/dL and/or greater
than 10% but less than 60% bone marrow clonal plasma
cells [3]. It is an intermediate stage between MGUS and
symptomatic MM. Most patients with SMM progress to
symptomatic myeloma; however, these patients can remain
stable over long periods of time. It is important for these
patients to be imaged regularly to determine the presence
of any bone lesions to look for disease progression [3].
Solitary plasmacytoma is defined as proliferation of
clonal plasma cells without evidence of significant bone
marrow plasma cell infiltration. Two separate entities have
been described: solitary plasmacytoma of bone (SPB) and
solitary extramedullary plasmacytoma. The distinction
between solitary extramedullary plasmacytoma and extraosseous multiple myeloma is based on radiological and
laboratory findings. In solitary plasmacytoma, no M protein is found in the serum and/or urine. The bone marrow
biopsy is not consistent with MM. Myeloma-related organ
or tissue impairment is not seen in solitary plasmacytoma.
In solitary plasmacytoma, there are no abnormalities such
as increased calcium levels, increased creatinine levels, or
decreased hemoglobin [3]. SPB constitutes approximately
5% of cases of plasma cell myeloma [7]. A little more than
half of patients with SPB progress to MM [8].
MM accounts for 1.3% of all malignancies and 15% of
hematologic cancers with men more frequently affected
than women and increased incidence in Africans and African Americans compared to whites [9]. It is almost always
preceded by MGUS or SMM. The definition of MM is
clonal bone marrow plasma cells greater than or equal
to 10% or biopsy proven bony or extramedullary plasmacytoma. Myeloma bone disease is defined as osteolytic
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lesions or presence of osteoporosis with compression fractures attributable to clonal plasma cell disorder [10].

Extraosseous multiple myeloma
Extraosseous multiple myeloma (EOMM) is the presence
of myeloma deposits outside the skeletal system. Although
considered rare, multiple autopsy series have demonstrated
the presence of extraosseous malignancies in approximately
63.5% of myeloma patients with lymph nodes, pleura, and
the liver most commonly involved [11]. In a study of 1003
consecutive patients, there was a suggestion that clinical or
radiological extraosseous disease is seen in almost 13% of
myeloma patients [12]. The study concluded the use of sensitive imaging techniques such as MRI and CT may partially
explain this finding. It also theorized the use of high dose
therapy and novel therapies with better supportive care led
to significant improvement of survival leading to increased
detection of extraosseous disease [12]. It is reported that
there is an increased incidence of extraosseous manifestations after autologous or allogenic stem cell transplantation [12]. It is theorized that extraosseous locations act as
sanctuary sites that are not successfully treated by the stem
cell transplantation and are the source of the higher rate of
extraosseous recurrence in these patients [13].
The clinical significance of EOMM is the association
with poorer survival rates and prognosis. It is associated
with shorter overall and progression free survival [12]. The
median survival after relapse of medullary myeloma with
subsequent development of extraosseous disease in the
course of MM in a single study was shown to be only 38
days [14]. Response to conventional treatment therapies are
found to be poor in extraosseous multiple myeloma. Therefore, it has become important for involved physicians and
radiologists to be familiar with extraosseous manifestations
of multiple myeloma as it significantly affects patients’ outcomes and treatment [15].
With the advancements made in cross sectional imaging
(CT/MRI) and increased availability of functional imaging
such as FDG PET, imaging has become an integral component of staging multiple myeloma. Cross sectional and
functional imaging has contributed to the increased detection of EOMM [15]. Ultrasound and CT fluoroscopy are
useful in percutaneous tissue biopsy of suspected sites of
extraosseous disease [15].

Extraosseous multiple myeloma pathology
appearance
On hematoxylin and eosin stain (H&E stain), EOMM has
a characteristic appearance. Tissues are diffusely infiltrated
by plasma cells which appear as ovoid cells with abundant
deep blue cytoplasm. These plasma cells have characteristic
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appearance on H&E stain which differentiates them from
B-lymphocytes. Plasma cells have eccentric nuclei and
exhibit perinuclear clearing which appears on H&E stain as
a halo surrounding the nucleus or a clearing corresponding
to the Golgi apparatus [16]. All plasma cells regardless of
abnormalities are detectable by their expression of certain
antigens on the cytoplasmic membrane. CD38 and CD138;
also known as syndecan-1 are expressed by plasma cells and
CD20 and CD19 antigens are not [17]. CD138 and CD38 are
commonly used to detect plasma cells with these antigens on
the cell membrane characteristically staining as a brown rim
and are present in nearly all cases [17]. Abnormal plasma
cells as seen in primary extraosseous plasmacytoma have
abnormal weak expression of CD56, which is not seen in
extraosseous myeloma [18].

Abdominal and pelvic extraosseous manifestations
of multiple myeloma
Extraosseous multiple myeloma frequently affects the
solid organs of the upper abdomen. Common affected sites
include the liver, kidney, pancreas, and the lymph nodes with
less common involvement of the bowel and gonads.
Liver
EOMM can affect any organ in the abdomen and pelvis;
however, the liver is most frequently involved according to
multiple autopsy series [11, 19]. The reported incidence of
hepatic involvement is in the range of 28–30% in autopsy
studies [11]. The most common pattern of involvement per
multiple autopsy studies is diffuse plasma cell infiltration
with nodular involvement being less common. Symptomatology varies from asymptomatic to hepatomegaly, jaundice,
and ascites to fulminant liver failure.
By imaging, hepatic involvement may be diffuse, unifocal, or multifocal. Diffuse involvement can be due to
innumerable lesions or occasionally be organ infiltration
(Fig. 1). Multifocal pattern of involvement usually presents
with hepatomegaly with innumerable small low attenuating
lesions which is the appearance we have most commonly
seen [15, 20]. Focal pattern of involvement on ultrasound
has been noted to be hypoechoic or target/bullseye in character. On CT, focal lesions are generally described as low
attenuating without calcification or significant contrast
enhancement [21]. On MRI, focal lesions may be hyper- or
hypointense on T1-weighted images and hyperintense on
T2-weighted images with minimal gadolinium enhancement [22]. In our experience, when multiphasic post-contrast
imaging is performed with either CT or MRI, myelomatous
lesions in the liver are commonly hypervascular on late
arterial phase imaging and low attenuating on venous phase

images (Fig. 2). EOMM in the liver is commonly hypermetabolic on 18-FDG PET-CT (Fig. 3).
Spleen
Splenic involvement is seen in almost 30–45% of patients
on autopsy [15]. It is most commonly seen in MM patients
with splenomegaly and affects approximately two thirds of
these patients [11, 19]. It is usually seen in the association
of hepatic involvement. The literature on splenic involvement in MM is sparse. The most common imaging finding of
splenic involvement is enlargement with diffuse infiltration
and less commonly focal masses (Fig. 4) [15].
Renal
Renal involvement is estimated to occur in 10–30% according to autopsy reports with it being the most common site
after the reticuloendothelial system [11, 19]. Symptoms of
renal involvement are usually asymptomatic or may present
with vague flank pain [22]. However, involvement of kidneys
has been infrequently reported on imaging. Renal extraosseous myeloma presents as renal and/or perirenal masses that
may be unilateral or bilateral. Limited literature demonstrate
that the most common imaging finding of renal involvement
of MM is a non-specific mass arising from the kidney, perirenal space, or retroperitoneum [20]. Less commonly when
these masses become large, retroperitoneal masses may
encase vessels and have a similar appearance to lymphoma
[20]. In our experience, we have more commonly encountered infiltrative retroperitoneal masses encasing the kidney.
On ultrasound renal myelomatous lesions are hypoechoic to
anechoic with increased blood flow to the lesion on Doppler
[15, 23] (Fig. 5). On CT, the masses are usually homogeneous and may show moderate to intense contrast enhancement
[15, 22]. On MR, the masses have been described to demonstrate heterogeneous signal intensity on T2-weighted images
with focal areas of high signal (Fig. 6) [20].
Adrenal
Adrenal involvement of multiple myeloma is rare and mostly
limited to case reports. Generally, patients are asymptomatic
as majority of the reported cases were non-functioning
tumors that were found incidentally on imaging [24, 25].
The most common imaging findings are heterogeneous,
well-circumscribed, unilateral soft tissue density adrenal
lesions (Fig. 7) [26]. Less commonly, there is bilateral adrenal involvement which has been reported in a case study by
Li et al [27]. Larger lesions have been described to demonstrate central necrosis and heterogeneous enhancement [20].
MRI findings demonstrate heterogeneous signal intensity on
both T1- and T2- weighted sequence with heterogeneous
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Fig. 1  A 68-year-old female presented with weight loss and new
onset jaundice. MRI was performed as part of the workup. Axial MR
T2 fat-saturated (a), T1 fat-saturated (b), T1 fat-saturated late arterial
phase post-contrast (c), and T1 fat-saturated venous phase post-contrast (d) of the liver demonstrate infiltrative perivascular soft tissue

pattern (white arrows) with increased T2 signal, decreased T1 signal,
mild arterial phase hyperenhancement, and mild venous phase washout. A CT fluoroscopic guided core biopsy of the periportal soft tissue revealed plasma cell neoplasm. Subsequent bone marrow biopsy
confirmed multiple myeloma

enhancement [20]. Unlike adrenal adenomas, these lesions
do not demonstrate signal dropout on opposed phase imaging [21].

have demonstrated avid enhancement on arterial phase, thus
they have often been mistaken as neuroendocrine tumors of
the pancreas [28]. Further MRI characteristics demonstrates
these masses as hypointense to isointense on T1-weighted
images and hyperintense on T2-weighted images relative to
pancreatic parenchyma (Fig. 9) [29].

Pancreas
Many autopsy studies demonstrate extraosseous involvement
in the pancreas that range between 4 and 17% [11, 19]. Most
patients are asymptomatic, but rarely may cause symptomatic obstructive jaundice when located in the pancreatic
head (Fig. 8). Pancreatic involvement most commonly present as solitary well-defined soft tissue masses with rare
reports of multifocal masses or diffuse involvement [20].
On ultrasound, lesions are heterogeneous, hypoechoic and
may cause biliary obstruction when located in the pancreatic head [15]. On multiphase CT or MR, pancreatic masses
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Lymph nodes
Tumor involvement of lymph nodes have been seen in
5–23% on autopsy studies [11, 19]. The most common sites
of lymph node involvement were paratracheal, parasplenic,
and supraclavicular nodes [11]. Imaging findings of lymph
node involvement are enlarged discrete or conglomerate
lymph nodes involving multiple nodal stations that enhance
after contrast [28]. These are frequently T2 hyperintense
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Fig. 2  An 87-year-old male presents with history of diffuse osseous multiple myeloma who underwent routine surveillance imaging. Axial contrast-enhanced portal venous phase CT of the liver (a)
demonstrates small scattered hypoattenuating masses. Subsequent,
multiphasic MRI including T1 MR post-contrast arterial phase (b)
and T1 MR post-contrast venous phase images (c) demonstrate hyper-

enhancing nodules with washout on portal venous phase images
(white arrows). A CT fluoroscopic guided core liver mass biopsy was
performed, yielding metastatic myeloma. H&E stain at 200 magnification (d) of the liver biopsy shows complete replacement of liver
parenchyma by numerous deep blue staining plasma cells

similar to pathologic lymph nodes in other neoplasms but
subtle low T2 signal have been reported on MR imaging
[15]. Involved lymph nodes are hypermetabolic on 18-FDG
PET-CT (Fig. 10).

thickening without causing significant luminal obstruction that mimics the appearance of lymphoma [15, 20]
(Figs. 11,12). Less commonly, involvement of the bowel can
appear as homogeneous soft tissue masses, which may be
eccentric in location, lobulated, mural or intraluminal [13].
In our experience, we have most commonly encountered
non-obstructing circumferential mural infiltration.

Gastrointestinal
In order of most to least common site of myelomatous gastrointestinal involvement is the small bowel, stomach, colon,
and esophagus. In autopsy series, fewer than 5% of patients
have gastrointestinal tract involvement [11, 19]. Clinical
symptoms, if present, are mainly dependent on the size of
the lesion that can cause abdominal pain, obstruction, intussusception, bleeding, fistula formation, and perforation [30].
The most common imaging appearance that has been
reported is a large mass with mural infiltration and wall

Testicular
Testicular involvement is extremely rare even on autopsy
reports. Typically, it presents as painless unilateral or bilateral testicular swelling late in the course of the disease
and is associated with a poor prognosis [31]. The most
reported ultrasound findings of testicular involvement are
diffuse enlargement then less commonly solitary or multiple
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Fig. 3  A 79-year-old male with a long-standing history of multiple
myeloma, recurrence after two prior stem cell transplants and a history of multiple extraosseous plasmacytomas presented with new
liver lesions on PET-CT. Axial (a) and coronal (b) fused 18-FDG

PET-CT images demonstrate multiple hypermetabolic foci that were
not biopsied and treated presumptively as hepatic myeloma (white
arrows)

Fig. 4  A 62-year-old female with new diagnosis of multiple myeloma
confirmed by marrow biopsy with 100% replacement of the marrow by plasma cell myeloma demonstrates non-specific hepatic and
splenic enlargement on non-contrast axial (a) and coronal (b) CT of

the abdomen (white arrows). The patient expired several weeks later,
and autopsy confirmed diffuse hepatic and splenic involvement by
multiple myeloma

testicular lesions [13, 28, 32]. Imaging findings can mimic
other pathology such as lymphoma or sarcoidosis. In a few
cases, diffuse enlargement or solitary or multiple hypoechoic
lesions are seen on ultrasound (Fig. 13) [28, 32]. MR imaging of a reported case of testicular involvement showed
enlarged testes with abnormal heterogeneous signal intensity [28].

Ovarian
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Ovarian involvement by myeloma is quite rare presenting
as a solid ovarian mass indistinguishable from an ovarian primary neoplasm (Fig. 14). The literature on plasma
cell disorders involving the ovary is sparse and primarily
consists of case reports of ovarian plasmacytoma and a
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Fig. 5  A 64-year-old female with a history of multiple myeloma presented to the emergency room with a history of hematuria and difficulty urinating. CT Urogram reveals an infiltrating mass in the left
renal hilum extending into the retroperitoneum and a large left sacral
mass extending toward the left bladder trigone (not shown). Axial
contrast-enhanced nephrogram phase CT (a) shows a large infiltrating soft tissue mass centered in the left renal sinus which demonstrates mild enhancement (white arrow). Axial excretory phase CT

(b) demonstrates compression of the renal collecting system by the
mass without significant obstruction. Transverse US (c) on the same
patient shows a hypoechoic renal sinus mass (white arrow) with loss
of tissue planes with the parenchyma and mild hydronephrosis. Sacral
and renal mass image-guided core biopsies were consistent with
plasma cell myeloma. H&E stain at 200 magnification (d) of the renal
biopsy shows numerous plasma cells replacing normal structures. The
patient received initial treatment with nephrostomy

single case of bilateral ovarian involvement in the setting
of disseminated myeloma [33–37]. In the myeloma patient,
the masses were relatively large measuring greater than
10 cm in diameter [36]. A similarly large size has been
seen in the ovarian plasmacytoma patients [35]. There are
limited descriptions of the imaging appearance but ovarian
plasmacytomas have been described as being metabolic
on 18-FDG PET-CT and large and heterogenous on CT
scan [33, 37].

Subcutaneous/muscular
Myelomatous deposits may occur in the subcutaneous tissues or within the muscles. The skin is a frequent site that
may manifest as subcutaneous palpable masses with a purplish hue with or without purpura [28]. Imaging findings
usually demonstrate well-defined subcutaneous nodules/
masses but may also be diffusely infiltrating lesions within
the subcutaneous tissues/muscles that may infiltrate into
adjacent organ structures (Fig. 15).
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Fig. 6  A 65-year-old female with a history of multiple myeloma and
biopsy-proven urinary bladder extraosseous myeloma presented for
suspected retroperitoneal bleed versus mass. Axial MR images: T2
fat-saturated (a), diffusion-weighted imaging b=600 (b), T1 pre-contrast, (c) and T1 fat-saturated post-contrast (d) through the kidneys
show extensive abnormal left sided renal/perirenal soft tissue infil-

trating much of the left retroperitoneum (white arrows) and extending across the midline toward the right renal hilum with vascular
encasement. This abnormal soft tissue demonstrates mildly increased
T2 signal with restricted diffusion and avid enhancement on postgadolinium images. Image-guided core biopsy revealed plasma cell
myeloma

Conclusion

but generally consist of enhancing soft tissue masses [13].
It should be considered in the differential diagnosis when
confronted with a patient with a history of MM presenting
with an intra-abdominal mass. If the myeloma patient is
presenting after stem cell transplantation the suspicion for
extraosseous myeloma should be increased. Familiarity
with the wide array of imaging appearances of extraosseous multiple myeloma in the abdomen and pelvis is useful
when the radiologist is confronted with an unknown mass
in the multiple myeloma patient.

Multiple myeloma is an uncommon malignancy, primarily affecting the bone marrow. A small portion of these
patients will develop extraosseous manifestations of their
disease, usually in the form of an extraosseous mass. This
is associated with a poorer prognosis and shorter survival
time. The most common locations of extraosseous multiple myeloma include the liver, pancreas, mesentery, and
retroperitoneum [20]. The imaging findings are variable,
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Fig. 7  A 68-year-old female with longstanding history of osseous
multiple myeloma and prior failed auto stem cell transplant had a CT
Thorax for evaluation of pneumonia with new incidentally noted liver
and adrenal lesions (not shown). These were subsequently evaluated
with abdominal MR and PET-CT. Axial MR T2 fat-saturated image
(a) and T1 fat-saturated image (b) demonstrate a T2 hyperintense
and T1 isointense to muscle right adrenal mass (white arrow) which
demonstrates avid enhancement on axial MR T1 fat-saturated post-

contrast image (c). Axial fused 18-FDG PET-CT (d) shows intense
hypermetabolism in the right adrenal mass (white arrow). Multiple
hypermetabolic osseous lesions, liver lesions, and retroperitoneal
masses were also present on the PET-CT (not shown). Repeat bone
marrow aspirate confirmed recurrent plasma cell myeloma. Treatment
was initiated and the adrenal mass and other abnormalities resolved
on follow-up imaging (not shown)
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Fig. 8  An 82-year-old male with a prior history of multiple myeloma
presented with nausea, vomiting, weakness, and jaundice. Axial (a)
and coronal (b) contrast-enhanced venous phase CT images of the
upper abdomen show an enhancing ampullary mass (white arrows)
causing dilation of the common bile duct and pancreatic duct (dashed
arrows). Axial MRI T1 fat-saturated post-contrast (c) and coronal T2

image (d) through the pancreatic head demonstrate T2 hypointense
and avidly enhancing ampullary mass extending into the pancreas
(white arrows) with common duct dilatation (dashed arrows). Esophagogastroduodenoscopy, sphincterotomy with endoscopic ultrasoundguided biopsy was consistent with plasmacytoma

Fig. 9  A 63-year-old female with a history of multiple myeloma,
status post bone marrow transplant presented with dizziness and
obstructive jaundice and disease progression based on bone marrow
aspirate. Coronal T2 (a) and axial T1 post-contrast (b) images dem-

onstrate a large enhancing peripancreatic mass that encases the distal
common bile duct and portal splenic confluence (white arrows). Incidental note of gallstones. Endoscopic US biopsy was non-diagnostic.
Patient entered hospice care and expired shortly afterwards
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Fig. 10  A 68-year-old female presented with weight loss and jaundice. Axial contrast-enhanced venous phase CT (a) demonstrates
mildly enlarged retroperitoneal lymph nodes (white arrow). On MRI,
the lymph nodes (white arrows) are moderately hyperintense on axial
T2 fat-saturated image (b), restrict diffusion on diffusion-weighted

image b=600 (c) and moderately enhanced on post-contrast T1 fatsaturated image (d). The MR of the abdomen also showed hepatic
involvement (Fig. 1). Myeloma was confirmed with a liver biopsy and
bone marrow aspirate
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Fig. 11  A 77-year-old female presented with a 12-pound weight loss
and abdominal pain underwent a CT scan of the abdomen and pelvis.
Axial (a) and coronal (b) contrast-enhanced venous phase CT images
illustrate a soft tissue mass along the wall of the 1st and 2nd portion
of duodenum with luminal narrowing (white arrows). Incidental note
of gallstones. Esophagogastroduodenoscopy and biopsy following the
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CT was consistent with duodenal plasmacytoma. H&E stain at 200
magnification (c) of the duodenal biopsy shows expansion of the lamina propria with monotonous proliferation of numerous plasma cells.
CD138 stain (d) has strongly positive membranous staining manifested as brown rim surrounding the cells (white arrow). Follow-up
bone marrow biopsy revealed multiple myeloma
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Fig. 12  A 69-year-old female with a remote history of MGUS and
subsequent diagnosis of multiple myeloma presented with abdominal
pain and an upper gastrointestinal bleed. Axial (a) and coronal (b)
contrast-enhanced venous phase CT images of the pelvis show two
adjacent segments of small bowel wall thickening (white arrows) in
the right lower quadrant without obstruction. Subsequent axial (c)

and coronal (d) fused 18-FDG PET-CT images show hypermetabolic
activity in the thickened small bowel loops (white arrows) in addition
to metabolic abnormalities in the mediastinum and ribs (not shown).
Incidental note of calcified uterine fibroids. CT-guided core biopsy of
small bowel was consistent with plasma cell neoplasm

Fig. 13  49-year-old male with known multiple myeloma, presented
with acute mental status changes, extensive central nervous system involvement including brain lesions and diffuse leptomeningeal
spread, diagnosed by positive cerebral spinal fluid. Testicular US per-

formed for testicular swelling. Grayscale US images of the right (a)
and left (b) testes show enlarged, heterogeneous bilateral testes with
multiple hypoechoic masses. These were clinically treated as myeloma given the disease burden elsewhere
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Fig. 14  An 84-year-old female presented with several week history
of weight loss and fatigue and acutely developed right leg swelling.
US revealed a right lower extremity deep venous thrombosis. Subsequent contrast-enhanced CT scan of the abdomen and pelvis in
venous phase axial (a) and coronal (b) images show a large, heterogeneously enhancing soft tissue mass in the right pelvis, involving
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the right ovary (white arrows). Patient underwent open resection. The
ovarian mass was a plasmacytoma. Gross oophorectomy specimen (c)
shows a 14 x 12 x 7.5 cm multicystic mass replacing the ovary. H&E
stain (d) shows sheets of monotonously appearing plasma cells which
efface the right ovary parenchyma. Bone marrow aspirate was negative for multiple myeloma

Abdominal Radiology

Fig. 15  A 61-year-old female with a history of multiple myeloma presented with a 2-month history of a palpable subcutaneous abdominal
masses. Axial fused 18-FDG PET-CT (a) and corresponding noncontrast axial CT images (b) through the lower abdomen show hyper-

metabolism within numerous infiltrative and nodular masses within
the subcutaneous tissues of the abdominal wall. Open surgical biopsy
was consistent with soft tissue myeloma
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